ACTIVITY OF VORICONAZOLE (UK-109,496) AGAINST CLINICAL ISOLATES OF ASPERGILLUS SPECIES AND ITS EFFECTIVENESS IN AN EXPERIMENTAL-MODEL OF INVASIVE PULMONARY ASPERGILLOSIS

Voriconazole, a new azole antifungal agent, showed potent activity aga inst clinical isolates of Aspergillus spp. in vitro. For A. fumigatus, the MIC range was <0.03 to 0.5 mu g/ml and the MIC at which 90% of is olates are inhibited was 0.25 mu g/ml. In an experimental model of inv asive pulmonary aspergillosis which mimics infection in humans, oral v oriconazole at dosages of 30 mg/kg of body weight per day significantl y delayed or prevented mortality.